

Erfolgreiche Teilnahme an Ringversuchen:

2025

- BRAF Mutationsanalyse (MolPath)
- HER2 Magenkarzinom / HER2 Gastric Carcinoma (IHC)

2024

- TBC (MolPath)
- Mammakarzinom: HER2, ER, PR, Ki-67 (IHC)
- External Quality Assurance Scheme (EQA-36, Robert Koch Institut) (EM Virus Diagnostic)

2023

- MGMT-Promotermethylierungsanalyse im Glioblastom (MolPath)
- CD117 (IHC)
- P16 HNSCC (IHC)

2022

- RAS Mutationsanalyse (MolPath)
- BRAF-Mutationsanalyse (MolPath)
- IDH1/IDH2 Mutation Analysis in Gliomas (MolPath)
- Mammakarzinom: HER2 (ISH)
- Neuroendokrine Marker: Synaptophysin, Chromogranin, MIB1 (IHC)
- Neuroendokrine Marker: Calcitonin (Erweiterung 1) (IHC)
- Keratine/Prostatakarzinom (IHC)

2021

- KRAS p.G12C NSCLC (MolPath)
- RAS Mutationsanalyse (MolPath.)
- RET Fusionen (ISH)
- Her2 Magenkarzinom (ISH)
- CD 117 (IHC)
- Mammakarzinom: Östrogen-Rezeptor (IHC)
- Defiziente DNA-Mismatch-Repair (IHC)
- p16 HNSCC (IHC)
- PD-L1 NSCLC, TPS (IHC)
- PD-L1 Urothelkarzinom (IHC)
- PD-L1 HNSCC (IHC)
- PD-L1 Magenkarzinom (IHC)

2020:

- BRAF V600E Kolon (MolPath)
- EGFR Gewebe (MolPath)
- RAS-Mutationsanalyse (MolPath)
- HER-2/neu ISH, Mammakarzinom (ISH)
- HER2-Magen (IHC)
- Keratine / Prostata (Pan-Keratin, Basalzell-Marker, Keratin 7, Keratin 20, Racemase, PSA) (IHC)